TS-1 (Colorectal Cancer) – Forecast and Market Analysis to 2023

Pages: 56 Published: November 01, 2014 Report Code: GDHC474DFR

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    iSpeech

GlobalData has released its new PharmaPoint Drug Evaluation report, “TS-1 (Colorectal Cancer) – Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended. Taiho Pharmaceutical’s TS-1 is a combination chemotherapy that consists of tegafur (a pro-drug of 5-FU) and two agents, gimeracil and oteracil, which decrease the rate of degradation of the 5-FU anti-metabolite. TS-1 was originally approved for the treatment of gastric cancer in Japan in 1999.The drug subsequently gained Japanese approval for colorectal cancer in 2003, and is also approved for other indications, including NSCLC and breast cancer (Shirasaka, 2008). TS-1 is not approved for the treatment of CRC in the US or 5EU, and no late-stage trials for this indication are currently ongoing in these regions (Taiho Oncology, 2014).

Scope

Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on TS-1 including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for TS-1 for the top country from 2013 to 2023.

Sales information covered for Japan.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of TS-1 performance

Obtain sales forecast for TS-1 from 2013-2023 in top country (Japan)

Table of Contents

1Table of Contents

1.1List of Tables

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Clinical Staging

3.3Symptoms

4Disease Management

4.1Diagnosis and Treatment Overview

4.1.1Screening and Diagnosis

4.1.2Treatment Guidelines and Leading Prescribed Drugs

4.1.3Clinical Practice

5Competitive Assessment

5.1Overview

6TS-1 (Tegafur, Gimeracil, Oteracil)

6.1Overview

6.2Efficacy

6.3Safety

6.4SWOT Analysis

6.5Forecast

7Appendix

7.1Bibliography

7.2Abbreviations

7.3Methodology

7.4Forecasting Methodology

7.4.1Diagnosed Colorectal Cancer Patients

7.4.2Percent Drug-Treated Patients

7.4.3General Pricing Assumptions

7.4.4Average Body Weight and Surface Area Across the 8MM

7.4.5Individual Drug Assumptions

7.4.6Generic Erosion

7.5Primary Research – KOLs Interviewed for this Report

7.6Primary Research – Prescriber Survey

7.7About the Authors

7.7.1Analyst

7.7.2Global Head of Healthcare

7.8About GlobalData

7.9Disclaimer

List of Tables

Table 1: TNM and Staging Classification System for CRC

Table 2: Symptoms of Colorectal Cancer

Table 3: Treatment Guidelines for CRC

Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013

Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013

Table 6: Leading Treatments for CRC, 2014

Table 7: Product Profile – TS-1

Table 8: TS-1 SWOT Analysis, 2014

Table 9: Global Sales Forecasts ($m) for TS-1, 2013-2023

Table 10: Average Body Weight and Surface Area Across the 8MM

Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

N/A

$3495

Can be used by individual purchaser only

$10485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.